Bad Soden am Taunus, Germany

Kurt Kebeler

This inventor holds 1 USPTO granted patent. Top assignee: Hoechst Aktiengesellschaft. Active years: 1992.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1992

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kurt Kebeler: Innovator in Medicinal Chemistry

Introduction

Kurt Kebeler is a notable inventor based in Bad Soden am Taunus, Germany. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative patent work. His expertise and dedication to research have led to advancements in pharmaceutical preparations.

Latest Patents

Kurt Kebeler holds a patent for "Substituted 3-thia- and 3-oxa-alkylflavones." This patent describes a process for the preparation of these compounds, which are represented by a specific formula. The compounds have potential uses as medicaments and in pharmaceutical preparations. Additionally, the patent outlines new intermediates for the preparation of these compounds, showcasing Kebeler's innovative approach to medicinal chemistry.

Career Highlights

Kurt Kebeler has had a distinguished career, working at Hoechst Aktiengesellschaft, a prominent company in the pharmaceutical industry. His work has been instrumental in developing new medicinal compounds that can improve health outcomes. With a focus on innovation, Kebeler has dedicated his career to advancing the field of chemistry.

Collaborations

Throughout his career, Kurt Kebeler has collaborated with esteemed colleagues, including Gerhard Beck and Ulrich Schacht. These collaborations have fostered a productive environment for research and development, leading to significant advancements in their respective fields.

Conclusion

Kurt Kebeler's contributions to medicinal chemistry through his patent work and collaborations highlight his role as an innovator in the industry. His dedication to research continues to influence the development of new pharmaceutical compounds.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…